Amgen beats estimates as standby drugs pump out growth; Strides Arcolab responds to FDA on plant lapses;

@FiercePharma: ICYMI yesterday: Pfizer unit pleads guilty, agrees to pay $491M in off-label marketing case. Report | Follow @FiercePharma

@CarlyHFierce: Rumors swirling about an AstraZeneca Celltrion buyout, but the Korean co. says nothing is definite. Celltrion's statement | Follow @CarlyHFierce

> Amgen ($AMGN) raised its full-year forecast as strong growth of its top drugs pushed second-quarter sales past analyst estimates; a one-time reimbursement adjustment also contributed to the 4.5% revenue increase. Report

> Strides Arcolab, one of the Indian companies under FDA scrutiny for manufacturing lapses, has submitted its response to the agency and continues to ship its products to the U.S., its CEO told Reuters. Report

> Belgian drugmaker UCB fell short on quarterly profits as its epilepsy drug Vimpat delivered lower-than-expected sales; it's older seizure treatment Keppra outperformed expectations on emerging markets growth. Report

> GlaxoSmithKline's ($GSK) Nigeria unit said its half-year pretax profit grew to 2.09 billion naira (about $13 million), with sales up to 13.99 billion naira; GSK last week gave up on plans to increase its stake in the business. Report

> Two South Florida pain doctors whose patients had died of overdoses were cleared of causing the deaths, but convicted of money laundering in a scheme involving a chain of "pill mills." Report

Medical Device News

@FierceMedDev: Alere's losses triple as investor fight awaits. Story | Results | Follow @FierceMedDev

@MarkHFierce: Italy's Sorin has finally recovered from earthquake-related earnings challenges. Story | Follow @MarkHFierce

@DamianFierce: Siemens: Löscher's out; Kaeser's in; revenue's still sagging. Much more here: Report | Follow @DamianFierce

> BD joins effort to boost lab quality in China and India. Item

> Qiagen unveils $100M share repurchase plan as income improves. Report

> Trovagene hauls in $15M for diagnostics R&D. Story

Biotech News

@FierceBiotech: From FierceBiotechIT.com: Ex-Yahoo CEO backs genomics big data startup Bina. Article | Follow @FierceBiotech

@JohnCFierce: AstraZeneca commits $815M to partner with FibroGen on anemia drug. News | Follow @JohnCFierce

@RyanMFierce: There are no drugs approved specifically for Fragile X, a top genetic cause of autism and intellectual disability. More | Follow @RyanMFierce

@EmilyMFierce: New compound could combat castration-resistant prostate cancer. Story | Follow @EmilyMFierce

> NIH awards Third Rock startup up to $10M for Fragile X work. Item

> Buzz: Hungry AstraZeneca circles a blockbuster biosimilars buyout. Report

> Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth. Article

> Report: Alexion allies with Goldman as Roche buyout rumor blazes. More

Drug Delivery News

@MichaelGFierce: Swedish team creates 'impossible' record-breaking drug delivery material. More | Follow @MichaelGFierce

> Mallinckrodt, Depomed win priority review for oral pain med. Report

> Aussie method makes for smaller, more efficient inhaled drugs. More

> DNA-based molecular robots zero in on cancer, autoimmune diseases. Article

> Mercator snags FDA patent for blood-pressure drug delivery catheters. Item

And Finally... Cancer experts say definitions of the disease should be refined to exclude the C-word from some less-serious diagnoses. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.